Leuven.Inc Ondernemerscafé ThromboGenics

An integrated biopharmaceutical company focused on developing innovative ophthalmic and oncology medicines.

ThromboGenics’ lead product JETREA^® (ocriplasmin) is the first approved pharmacological treatment for symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT).

The US Food and Drugs Administration (FDA) approved JETREA^® for the treatment of symptomatic VMA in October 2012. ThromboGenics launched the drug in the US by its own commercial organization in mid-January 2013.

In March 2013, the European Commission approved JETREA^® for VMT, including when associated with macular hole of diameter less than or equal to 400 microns. Alcon, ThromboGenics’ partner for the commercialization of JETREA^® outside the US, has now launched the drug in the UK, Germany, Denmark, Sweden, Norway and Finland.

Next to an overview of ThromboGenics, speakers will elaborate on their strategic partnership with Alcon (Novartis) for the commercialization of JETREA^® outside the United States as well as on the regulatory path, its challenges and learnings.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. 

Practical details

Date: Wednesday October 9th, 2013 (18h00 – 21h30)
Location: ThromboGenics, Bio-Incubator II, Gaston Geenslaan 1, 3001 Leuven

Programme

18h00:	Arrival participants
18h30:	Welcome by Leuven.Inc
18h40:	Introduction and overview of ThromboGenics Désiré Collen, Prof.em. KU Leuven, oprichter en huidig voorzitter, ThromboGenics
19h00:	JETREA® indication and mode of action Petra Kozma-Wiebe, Clinical Trials Physician, ThromboGenics
19h30:	Regulatory path for JETREA®: challenges and learnings Lene Rose Arfelt, Global Head Regulatory Affairs, ThromboGenics
20h00:	Q&A followed by a reception
21h30:	Closing of the Café

Registration

Registration before Wednesday 2 October, preferably via the online registration form (use the 'Register' button) or by email to admin@leuveninc.com (including all contact and invoice details).

Please note: Leuven.Inc Ondernemerscafés are a members-only activity.

For organizational reasons, the number of participants will be limited.
Company members (max. 2 persons/company) will have first priority to register till September 6.
After this date, individual members can register according to the 'first subscribe, first serve' principle.

After registration you will receive a confirmation and route description. 
May we kindly ask you to inform us in case you are not able to attend.